146 related articles for article (PubMed ID: 37414610)
1. Disparities in late and lost: Pediatricians' role in following Pompe disease identified by newborn screening.
Pillai NR; Fabie NAV; Kaye TV; Rosendahl SD; Ahmed A; Hietala AD; Jorgenson AB; Lanpher BC; Whitley CB
Mol Genet Metab; 2023; 140(1-2):107633. PubMed ID: 37414610
[TBL] [Abstract][Full Text] [Related]
2. A large-scale nationwide newborn screening program for Pompe disease in Taiwan: towards effective diagnosis and treatment.
Yang CF; Liu HC; Hsu TR; Tsai FC; Chiang SF; Chiang CC; Ho HC; Lai CJ; Yang TF; Chuang SY; Lin CY; Niu DM
Am J Med Genet A; 2014 Jan; 164A(1):54-61. PubMed ID: 24243590
[TBL] [Abstract][Full Text] [Related]
3. Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G "late-onset" GAA variant.
Rairikar MV; Case LE; Bailey LA; Kazi ZB; Desai AK; Berrier KL; Coats J; Gandy R; Quinones R; Kishnani PS
Mol Genet Metab; 2017 Nov; 122(3):99-107. PubMed ID: 28951071
[TBL] [Abstract][Full Text] [Related]
4. Health care practitioners' experience-based opinions on providing care after a positive newborn screen for Pompe disease.
Davids L; Sun Y; Moore RH; Lisi E; Wittenauer A; Wilcox WR; Ali N
Mol Genet Metab; 2021; 134(1-2):20-28. PubMed ID: 34602357
[TBL] [Abstract][Full Text] [Related]
5. Newborn screening for Pompe disease in Italy: Long-term results and future challenges.
Gragnaniello V; Pijnappel PWWM; Burlina AP; In 't Groen SLM; Gueraldi D; Cazzorla C; Maines E; Polo G; Salviati L; Di Salvo G; Burlina AB
Mol Genet Metab Rep; 2022 Dec; 33():100929. PubMed ID: 36310651
[TBL] [Abstract][Full Text] [Related]
6. Current status of newborn screening for Pompe disease in Japan.
Sawada T; Kido J; Sugawara K; Momosaki K; Yoshida S; Kojima-Ishii K; Inoue T; Matsumoto S; Endo F; Ohga S; Hirose S; Nakamura K
Orphanet J Rare Dis; 2021 Dec; 16(1):516. PubMed ID: 34922579
[TBL] [Abstract][Full Text] [Related]
7. Newborn screening for Pompe disease: Parental experiences and follow-up care for a late-onset diagnosis.
Prakash S; Penn JD; Jackson KE; Dean LW
J Genet Couns; 2022 Dec; 31(6):1404-1420. PubMed ID: 35915971
[TBL] [Abstract][Full Text] [Related]
8. Liquid Chromatography-Tandem Mass Spectrometry Assay of Leukocyte Acid α-Glucosidase for Post-Newborn Screening Evaluation of Pompe Disease.
Lin N; Huang J; Violante S; Orsini JJ; Caggana M; Hughes EE; Stevens C; DiAntonio L; Chieh Liao H; Hong X; Ghomashchi F; Babu Kumar A; Zhou H; Kornreich R; Wasserstein M; Gelb MH; Yu C
Clin Chem; 2017 Apr; 63(4):842-851. PubMed ID: 28196920
[TBL] [Abstract][Full Text] [Related]
9. Mass Spectrometry but Not Fluorimetry Distinguishes Affected and Pseudodeficiency Patients in Newborn Screening for Pompe Disease.
Liao HC; Chan MJ; Yang CF; Chiang CC; Niu DM; Huang CK; Gelb MH
Clin Chem; 2017 Jul; 63(7):1271-1277. PubMed ID: 28450385
[TBL] [Abstract][Full Text] [Related]
10. Pompe disease ascertained through The Lantern Project, 2018-2021: Next-generation sequencing and enzymatic testing to overcome obstacles to diagnosis.
Sniderman King L; Pan Y; Nallamilli BRR; Hegde M; Jagannathan L; Ramachander V; Lucas A; Markind J; Colzani R
Mol Genet Metab; 2023 May; 139(1):107565. PubMed ID: 37087815
[TBL] [Abstract][Full Text] [Related]
11. Outcome of Later-Onset Pompe Disease Identified Through Newborn Screening.
Lee NC; Chang KL; In 't Groen SLM; de Faria DOS; Huang HJ; Pijnappel WWMP; Hwu WL; Chien YH
J Pediatr; 2022 May; 244():139-147.e2. PubMed ID: 34995642
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics and genotypes in the ADVANCE baseline data set, a comprehensive cohort of US children and adolescents with Pompe disease.
Kishnani PS; Gibson JB; Gambello MJ; Hillman R; Stockton DW; Kronn D; Leslie ND; Pena LDM; Tanpaiboon P; Day JW; Wang RY; Goldstein JL; An Haack K; Sparks SE; Zhao Y; Hahn SH;
Genet Med; 2019 Nov; 21(11):2543-2551. PubMed ID: 31086307
[TBL] [Abstract][Full Text] [Related]
13. Newborn screening for Pompe disease: impact on families.
Pruniski B; Lisi E; Ali N
J Inherit Metab Dis; 2018 Nov; 41(6):1189-1203. PubMed ID: 29594646
[TBL] [Abstract][Full Text] [Related]
14. Description of clinical and genetic features of 122 patients included in the Spanish Pompe registry.
Martinez-Marin RJ; Reyes-Leiva D; Nascimento A; Muelas N; Dominguez-González C; Paradas C; Olivé M; García-Romero M; Pascual-Pascual SI; Grau JM; Barba-Romero MA; Gomez-Caravaca MT; de Las Heras J; Casquero P; Mendoza MD; de León JC; Gutierrez A; Morís G; Blanco-Lago R; Ramos-Fransi A; Pintós G; García-Antelo MJ; Rabasa M; Morgado Y; Usón M; Miralles FJ; Bárcena-Llona JE; Gómez-Belda AB; Pedraza-Hueso MI; Hortelano M; Colomé A; Garcia-Martin G; Lopez de Munain A; Jericó I; Galán-Dávila L; Pardo J; Salgueiro-Origlia G; Alonso-Pérez J; Pla-Junca F; Schiava M; Segovia-Simón S; Díaz-Manera J
Neuromuscul Disord; 2024 Jan; 34():1-8. PubMed ID: 38087756
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, safety profile, and immunogenicity of alglucosidase alfa produced at the 4,000-liter scale in US children and adolescents with Pompe disease: ADVANCE, a phase IV, open-label, prospective study.
Hahn SH; Kronn D; Leslie ND; Pena LDM; Tanpaiboon P; Gambello MJ; Gibson JB; Hillman R; Stockton DW; Day JW; Wang RY; An Haack K; Shafi R; Sparks S; Zhao Y; Wilson C; Kishnani PS;
Genet Med; 2018 Oct; 20(10):1284-1294. PubMed ID: 29565424
[TBL] [Abstract][Full Text] [Related]
16. Pompe disease: early diagnosis and early treatment make a difference.
Chien YH; Hwu WL; Lee NC
Pediatr Neonatol; 2013 Aug; 54(4):219-27. PubMed ID: 23632029
[TBL] [Abstract][Full Text] [Related]
17. Three cases of multi-generational Pompe disease: Are current practices missing diagnostic and treatment opportunities?
McIntosh P; Austin S; Sullivan J; Bailey L; Bailey C; Viskochil D; Kishnani PS
Am J Med Genet A; 2017 Oct; 173(10):2628-2634. PubMed ID: 28763149
[TBL] [Abstract][Full Text] [Related]
18. A Comprehensive Update on Late-Onset Pompe Disease.
Labella B; Cotti Piccinelli S; Risi B; Caria F; Damioli S; Bertella E; Poli L; Padovani A; Filosto M
Biomolecules; 2023 Aug; 13(9):. PubMed ID: 37759679
[TBL] [Abstract][Full Text] [Related]
19. Pompe disease in Austria: clinical, genetic and epidemiological aspects.
Löscher WN; Huemer M; Stulnig TM; Simschitz P; Iglseder S; Eggers C; Moser H; Möslinger D; Freilinger M; Lagler F; Grinzinger S; Reichhardt M; Bittner RE; Schmidt WM; Lex U; Brunner-Krainz M; Quasthoff S; Wanschitz JV
J Neurol; 2018 Jan; 265(1):159-164. PubMed ID: 29181627
[TBL] [Abstract][Full Text] [Related]
20. Phenotypic implications of pathogenic variant types in Pompe disease.
Viamonte MA; Filipp SL; Zaidi Z; Gurka MJ; Byrne BJ; Kang PB
J Hum Genet; 2021 Nov; 66(11):1089-1099. PubMed ID: 33972680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
